Stifel Nicolaus Issues Pessimistic Forecast for Cipher Pharmaceuticals (TSE:CPH) Stock Price

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its price target trimmed by Stifel Nicolaus from C$19.00 to C$17.00 in a report issued on Monday morning,BayStreet.CA reports.

A number of other equities research analysts also recently weighed in on CPH. Stifel Canada raised Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th. Leede Financial cut shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th.

Cipher Pharmaceuticals Stock Performance

TSE:CPH opened at C$12.79 on Monday. Cipher Pharmaceuticals has a twelve month low of C$5.03 and a twelve month high of C$19.69. The firm has a market cap of C$327.30 million, a price-to-earnings ratio of 10.23 and a beta of 1.20. The company has a 50-day moving average of C$16.07 and a 200-day moving average of C$12.30. The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings data on Thursday, November 7th. The company reported C$0.01 EPS for the quarter, missing analysts’ consensus estimates of C$0.03 by C($0.02). Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. The firm had revenue of C$14.15 million for the quarter, compared to analysts’ expectations of C$13.37 million. Analysts forecast that Cipher Pharmaceuticals will post 1.2907348 earnings per share for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.